Effect of Rosuvastatin on Outcomes in Chronic Haemodialysis Patients: Baseline Data from the AURORA Study

Bengt Fellström^a Hallvard Holdaas^b Alan G. Jardine^c Helen Rose^d
Roland Schmieder^e Wim Wilpshaar^f Faiez Zannad^g
on behalf of the AURORA Study Group

^aDepartment of Medical Science, Renal Unit, University Hospital, Uppsala, Sweden; ^bDepartment of Nephrology, Rikshospitalet, University of Oslo, Oslo, Norway; ^cBHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow; ^dAstraZeneca, Macclesfield, UK; ^eDepartment of Nephrology and Hypertension, Universitätsklinik, Erlangen-Nürnberg, Erlangen, Germany; ^fformer AstraZeneca, Macclesfield, UK and ^gClinical Investigation Centre INSERM (CIC), Hôpital Jeanne d'Arc, Toul, France

Key Words

Rosuvastatin • End-stage renal disease • Cardiovascular disease • Haemodialysis

Abstract

Background: Cardiovascular disease (CVD) is the leading cause of death in patients with end-stage renal disease (ESRD). **Aims:** AURORA (A study to evaluate the Use of Rosuvastatin in subjects On Regular haemodialysis: an Assessment of survival and cardiovascular events) is the first large-scale international trial to assess the effects of statins on cardiovascular outcomes in patients with ESRD on chronic haemodialysis. Preliminary baseline data from the randomised population are presented. **Methods:** A total of 2,775 patients from 280 centres in 25 countries were randomised into the study. Patients aged 50–80 years on regular chronic haemodialysis for at least 3 months before screening were eligible for inclusion. They were randomised 1:1 to receive either rosuvastatin 10 mg or placebo daily and assessed throughout the study. **Results:** The mean age at baseline was 64 years. Most patients were male (62%) and 85% were white. The median time since commencing renal

replacement was 32 months. Mean total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) levels were 4.53 mmol/l (175 mg/dl) and 2.57 mmol/l (99 mg/dl), respectively.

Conclusion: Results from the AURORA trial will impact on the current guidelines and use of statins in this patient population.

Copyright © 2007 S. Karger AG, Basel

Introduction

End-stage renal disease (ESRD) is the most advanced manifestation of chronic kidney disease (CKD). As the population ages and prevalence rates of type 2 diabetes increase, ESRD is set to be an increasing global problem. Worldwide, there are over 1 million patients with ESRD requiring dialysis, with an incidence of about a quarter of a million new patients each year [1]. Patients with ESRD have higher rates of hospitalisation than individuals without the disease [2, 3]. In the USA, treating patients with ESRD costs approximately USD 18 billion (6.6% of the Medicare budget) [3].

KARGER

Fax +41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com

© 2007 S. Karger AG, Basel
1420–4096/07/0305–0314\$23.50/0

Accessible online at:
www.karger.com/kbr

Professor Bengt Fellström
Department of Medical Science, Renal Unit, University Hospital
SE-751 85 Uppsala (Sweden)
Tel. +46 18 611 0000, ext. 4348, Fax +46 18 38304
E-Mail bengt.fellstrom@medsci.uu.se

Cardiovascular disease (CVD) is highly prevalent in patients with ESRD and it is the single largest cause of premature mortality in this patient group [4–7]. Controlling CVD risk factors in patients with ESRD has the potential to lower associated morbidity and mortality, and to thereby decrease the substantial burden on healthcare professionals and providers.

Several landmark trials have established the beneficial effect of statins (hydroxy-methylglutaryl-coenzyme A reductase inhibitors) in reducing cardiovascular morbidity and mortality [8–16]. Reductions in cardiovascular events have also been observed in patients treated with statins, but who do not have elevated cholesterol levels [13, 15, 16]. In addition, in the Heart Protection Study, the benefit of statin treatment was shown to be independent of baseline cholesterol levels [13].

Most patients on haemodialysis do not have elevated total cholesterol (TC) or low-density lipoprotein cholesterol (LDL-C) levels but they have other atherogenic lipid abnormalities, including low high-density lipoprotein cholesterol (HDL-C), elevated triglycerides (TG) and a higher proportion of intermediate and small, dense LDL particles [17–19]. In addition, oxidative stress, endothelial dysfunction and inflammation are all associated with decreasing renal function and dialysis in patients with ESRD [20–23], conditions that can help to promote atherosclerotic disease. As well as lowering LDL-C levels, statins have beneficial effects on other lipid parameters and have other (pleiotropic) effects, including anti-oxidant effects, improving endothelial dysfunction and lowering levels of C-reactive protein (CRP) [24–26].

Patients with ESRD have usually been excluded from outcome studies of statins because of their related comorbidities and issues over safety and pharmacokinetics, leading to a scarcity of clinical characteristics and outcome data for these patients. Moreover, very little comprehensive global prospective data of this kind is available for patients with ESRD undergoing chronic haemodialysis. However, observational data indicate that statin treatment may improve survival in patients with ESRD [27] and large-scale randomised studies with statins in this patient group are required to confirm these findings [28].

In Die Deutsche Diabetes Dialyse Studie (4D study), the effect of atorvastatin 20 mg compared with placebo on cardiovascular outcomes was assessed in 1,255 patients with type 2 diabetes receiving haemodialysis [29]. Atorvastatin did not significantly lower the incidence of the composite primary endpoint (death from cardiac causes, non-fatal myocardial infarction [MI], or fatal or

non-fatal stroke), although there were fewer events in the atorvastatin group (226 vs. 243 in the placebo group; relative risk [RR] 0.92, 95% confidence intervals [CI] 0.77–1.10; $p = 0.37$). Cases of fatal stroke occurred significantly more frequently in the atorvastatin group compared with the placebo group (RR 2.03, 95% CI 1.05–3.93; $p = 0.04$), contributing to the finding that the treatment effect on the primary endpoint was less than predicted. Atorvastatin reduced the rate of all cardiac events combined, compared with the placebo group (RR 0.82, 95% CI 0.68–0.99; $p = 0.03$).

There is a clear need for further long-term studies of patients with ESRD to clarify the role of statins on cardiovascular outcomes. Rosuvastatin is the most effective of the available statins for lowering LDL-C levels, as well as having benefits across the lipid profile [30, 31]. These properties make it an ideal agent for a study to investigate the benefits of statin treatment for the prevention of cardiovascular events in a population of patients at high risk of these events.

AURORA (A study to evaluate the Use of Rosuvastatin in subjects On Regular haemodialysis: an Assessment of survival and cardiovascular events) is the first large-scale international trial to assess the effects of a statin on cardiovascular morbidity and mortality in patients with ESRD on chronic haemodialysis, irrespective of baseline lipid levels. This report presents preliminary baseline data for patients randomised into the study.

Methods

Detailed methodology and the rationale for the AURORA study have been published previously [32].

Study Design

AURORA is a randomised, double-blind, multicentre, parallel-group, international, phase IIb study (fig. 1). Patients have been randomised into the study from 280 centres in 25 countries (table 1). They have been randomised (1:1) to receive either rosuvastatin 10 mg or placebo and are being assessed at regular intervals during the study.

The study is being conducted in accordance with the ethical principles of the Declaration of Helsinki, the International Conference of Harmonisation Good Clinical Practice guidelines and local regulatory requirements. All randomised patients provided written informed consent.

Patients

Men and women aged 50–80 years with ESRD and receiving regular chronic haemodialysis (inclusive of haemofiltration and haemodiafiltration) for at least 3 months were screened for eligibility.

Fig. 1. AURORA study design. Adapted from Fellström et al. [32] (BioMed Central Open Access article).

Major exclusion criteria included the likely requirement for kidney transplantation within 1 year; major haematological, neoplastic, metabolic (excluding diabetes), gastrointestinal or infectious disease that may reduce survival to <1 year; history of malignancy; statin therapy within the previous 6 months; active liver disease (alanine aminotransferase $>3 \times$ the upper limit of normal [ULN]); uncontrolled hypothyroidism (thyroid-stimulating hormone $>1.5 \times$ ULN); and unexplained creatine kinase $>3 \times$ ULN.

Endpoints

The efficacy endpoints will be analysed using the intention-to-treat population, which includes all randomised patients. Details of specific statistical analyses have been described previously [32].

The primary endpoint is the time to a major cardiovascular event (cardiovascular death, non-fatal MI or non-fatal stroke). All deaths, MIs and strokes are being reviewed and adjudicated by a Clinical Endpoint Committee (in a blinded manner) to ensure consistency of event diagnosis.

Secondary endpoints include all-cause mortality, cardiovascular event-free survival (cardiovascular death, non-fatal MI, non-fatal stroke or death from any other cause), cardiovascular death, noncardiovascular death, procedures as a result of stenosis or thrombosis of the vascular access for chronic haemodialysis (arteriovenous fistulas and grafts only), and coronary or peripheral revascularisations. In addition, the health economic impact of rosuvastatin treatment will be analysed.

In subsequent studies and pre-specified subgroup analyses, the assessment of the prognostic value of various blood markers (CRP, lipid parameters, parathormone, vitamin D₃, calcium phosphate product, asymmetrical dimethylarginine [ADMA], B-type natriuretic peptide [BNP], pregnancy-associated plasma protein A [PAPP-A], cardiotrophins and collagen parameters) and the potential interaction with rosuvastatin is planned. A sub-study on telomere length is also intended. Furthermore, the effect of mean systolic and diastolic blood pressure, and pulse pressure on the

Table 1. Distribution of randomised patients by country

Country	n	%
Brazil	253	9.1
UK	228	8.2
France	216	7.8
Canada	178	6.4
Poland	167	6.0
Germany	165	5.9
Australia	164	5.9
The Netherlands	151	5.4
Hungary	149	5.4
Sweden	109	3.9
Denmark	108	3.9
Czech Republic	99	3.6
Turkey	96	3.5
Mexico	93	3.4
Austria	91	3.3
Belgium	89	3.2
South Korea	82	3.0
Bulgaria	76	2.7
Italy	74	2.7
Finland	69	2.5
Norway	50	1.8
Greece	44	1.6
Switzerland	14	0.5
Iceland	5	0.2
Republic of Ireland	5	0.2
Total	2,775

Fig. 2. Prevalence of documented cardiovascular disease or risk equivalent at baseline. Y-axis truncated to 60% to improve the clarity of the data presented. Any = At least one cardiovascular disease or CVD risk equivalent; MI = myocardial infarction; CABG = coronary artery bypass graft; PAD = peripheral arterial disease; CAD = carotid artery disease; TIA = transient ischaemic attack.

primary and secondary variables will be performed in detail, with specific consideration of the potential impact of rosuvastatin.

Statistical Analysis

The statistical methodology has been published previously [32].

The Executive Steering Committee recently re-evaluated the underlying assumptions of the AURORA study in the light of recently reported studies in similar populations, particularly the 4D [29] and Assessment of LEscol in Renal Transplantation (ALERT) trials [33]. Although these studies observed a substantial reduction in the risk of MI with lipid-lowering therapy, no reduction was observed on stroke. This may indicate the presence of a non-modifiable endpoint in the composite primary endpoints of these studies. Therefore, the Executive Steering Committee recommended an assumption of a neutral (0%) treatment effect on strokes and that the assumed placebo annual event rate should be adjusted in line with the observed annual event rate and the revised overall expected treatment effect. These changes were also endorsed by the full Steering Committee.

These modifications were considered scientifically reasonable and necessary given the importance of the study to the medical community. The independent Data and Safety Monitoring Board (DSMB) supported these recommendations and the protocol was consequently amended, thus extending the study by an expected 7 months.

The revised sample size was therefore based upon an assumed cardiovascular event rate of 12% per year in the placebo group. To

detect a 19.5% reduction in cardiovascular event rate per year at a two-sided significance level of 4.719% (5% level adjusted for the interim analysis), with 87% power, the study should continue until approximately 805 patients have experienced a major cardiovascular event. This is expected to be 4.6 years after initiation of the study, which began in January 2003.

Interim Analysis

The DSMB performed an interim analysis when 305 patients had experienced a major cardiovascular event, as specified in the original protocol. All endpoints that occurred before or on March 17, 2005 were included in the analysis. The purpose was to investigate the possibility of concluding a significant difference between treatments for the time from randomisation to a major cardiovascular event. Following the interim analysis, the DSMB recommended to the Steering Committee and the study sponsor for the study to continue as planned.

Results

The AURORA study began in January 2003 and the last patient was randomised in December 2004. From approximately 3,020 patients who entered the screening period, 2,775 patients were randomised into the study from 25 countries in Europe, the Americas and Australasia (table 1).

Baseline characteristics of the patient population are shown in tables 2–4 and figure 2. Male patients comprised 62% of the population studied, and most patients were white. Mean age of the study population was 64 years, with patients aged between 50–59, 60–69 and 70–80 years equally represented. Mean body mass index (BMI) was 25 kg/m², with 301 (11%) patients <20 kg/m² and 430 (15.5%) patients ≥30 kg/m². Fifteen percent of patients were smokers. Mean systolic and diastolic blood pressure was 137 and 76 mm Hg, respectively (table 2).

The median time since commencing renal replacement therapy was 32 months with just under half (47%) of all patients on therapy for <2.5 years. A total of 2,547 (92%) patients were receiving standard haemodialysis and 228 (8%) patients were receiving haemofiltration/haemodiafiltration; the most common type of access was by arteriovenous fistula (79% patients). Most patients (75%) were spending from 10 to 14 h per week on dialysis (table 3).

Just over half (51%) of the patients had a history of documented CVD or CVD risk equivalent, with diabetes, angina and peripheral arterial disease recorded most frequently (26, 19 and 15%, respectively) (fig. 2).

Baseline laboratory parameters are shown in table 4. Mean TC and LDL-C levels were 4.53 mmol/l (175 mg/dl) and 2.57 mmol/l (99 mg/dl), respectively, and mean

Table 2. Characteristics of patients at baseline

	Randomised population (n = 2,775)
Male, n (%)	1,724 (62.1)
Mean age, years (SD)	64.2 (8.7)
Age group, n (%)	
<50 years ^a	3 (0.1)
50–59 years	968 (34.9)
60–69 years	900 (32.4)
70–80 years	901 (32.5)
>80 years ^a	3 (0.1)
Race, n (%)	
White	2,356 (84.9)
Black	98 (3.5)
Asian	139 (5.0)
Hispanic	113 (4.1)
Other	69 (2.5)
Mean BMI, kg/m ² (SD)	25.4 (4.9)
Mean blood pressure, mm Hg (SD)	
Systolic	136.9 (24.5)
Diastolic	75.8 (12.7)
Pulse pressure	61.2 (19.4)
Smoker, n (%)	429 (15.5)
Major cardiovascular disease or risk equivalents, n (%)	
Type 1 or 2 diabetes	718 (25.9)
Angina	524 (18.9)
Peripheral arterial disease	422 (15.2)
Myocardial infarction	281 (10.1)
^a Protocol deviators.	

HDL-C and TG levels were 1.16 mmol/l (45 mg/dl) and 1.75 mmol/l (155 mg/dl), respectively. Mean haemoglobin and haematocrit levels were within the target range recommended by international guidelines for patients with CKD [35, 36].

Discussion

AURORA is the first large-scale prospective international trial to assess the effects of a statin on cardiovascular morbidity and mortality in ESRD patients on chronic haemodialysis, irrespective of baseline lipid levels. It will provide the largest database of its kind, with structured, prospective data collection and all primary endpoints being adjudicated by a Clinical Endpoint Committee. AURORA has the potential to provide a representative picture of the effect of statin therapy on cardiovascular morbidity and mortality in patients on chronic haemodialysis.

Table 3. Dialysis parameters at baseline

	Randomised population (n = 2,775)
Median time since RRT started, months	32.0
Categories, n (%)	
Unknown	1 (0.04)
0 to <2.5 years	1,306 (47.1)
2.5 to <5.0 years	687 (24.8)
5.0 to <7.5 years	343 (12.4)
7.5 to <10.0 years	140 (5.0)
≥10.0 years	298 (10.7)
Median time since haemodialysis started, months	28.0
Categories, n (%)	
Unknown	1 (0.04)
0 to <2.5 years	1,467 (52.9)
2.5 to <5.0 years	699 (25.2)
5.0 to <7.5 years	320 (11.5)
7.5 to <10.0 years	122 (4.4)
≥10.0 years	166 (6.0)
Current dialysis treatment, n (%)	
Haemodialysis	2,547 (91.8)
Haemofiltration/haemodiafiltration	228 (8.2)
Filters/membranes, n (%)	
High flux	1,210 (43.6)
Low flux	1,565 (56.4)
Type of access, n (%)	
Arteriovenous fistula	2,202 (79.4)
Central dialysis catheter	316 (11.4)
Graft	239 (8.6)
Not recorded	18 (0.6)
Duration of dialysis	
Mean (SD), h/week	11.9 (1.8)
Categories, n (%)	
<10 h/week	295 (10.6)
≥10 to <14 h/week	2,077 (74.8)
≥14 h/week	402 (14.5)
Not recorded	1 (0.04)
Calculated Kt/V, mean (SD)	1.547 (0.369)

RRT = Renal replacement therapy; Kt/V = dialysis adequacy calculated from pre- and post-urea results [34].

Documented CVD and/or diabetes were present in half of the patients. The main lipid parameters at baseline were close to those observed in other studies of haemodialysis populations [19, 37, 38], although they did appear to differ from those reported in the 4D study: Mean $\pm$ SD baseline lipid levels in 4D: TC 220 $\pm$ 42 mg/dl in placebo and 218 $\pm$ 43 mg/dl in atorvastatin patients, LDL-C 127 $\pm$ 30 mg/dl in placebo and 125 $\pm$ 29 mg/dl in atorvastatin patients and TG 267 $\pm$ 168 mg/dl in placebo and 261 $\pm$ 165 mg/dl in atorvastatin patients – all higher lev-

els than in the AURORA patients at baseline; HDL-C was 36 ± 14 mg/dl in placebo and 36 ± 13 mg/dl in atorvastatin patients – lower than in AURORA patients at baseline [29, 39]. The difference in lipids at baseline between 4D and AURORA may be due to differing inclusion criteria: 4D only randomised patients with type 2 diabetes and excluded patients with fasting serum LDL-C levels of less than 80 mg/dl (2.1 mmol/l) or more than 190 mg/dl (4.9 mmol/l), whereas AURORA did not specify LDL-C levels or a history of diabetes in its inclusion criteria.

Mean baseline oxidised LDL levels (34.2 U/l) in AURORA were below levels previously observed in apparently healthy, middle-aged men from the general population (93 U/l) [40]. Diepeveen et al. [41] also report mean oxidised LDL levels in dialysis patients to be below those expected for the general population (42 U/l at baseline in the placebo arm), and they indicated that this may reflect the lower lipid levels present in these patients (mean $\pm$ SD), baseline LDL-C 2.7 ± 0.8 mmol/l in the placebo arm), which are similar to the baseline LDL-C levels in AURORA.

Outcome trials of statins in patients with conditions related to the disease profile of those enrolled in the AURORA trial include 4D [29, 39], ALERT [33] and SHARP (Study of Heart And Renal Protection [42]).

Data from the 4D study indicate the absence of a significant beneficial effect of atorvastatin on cardiovascular outcomes in patients with diabetes receiving haemodialysis, although a significant reduction in cardiac events

was observed (RR 0.82, 95% CI 0.68–0.99; $p = 0.03$). Cases of fatal stroke were observed more frequently in the atorvastatin group compared with the placebo group, although the number of these (27 [4%] and 13 [2%] of patients, respectively) was low. Atorvastatin significantly reduced the secondary endpoint of all cardiac events combined, compared with the placebo group (246 vs. 205 in the placebo group; RR 0.82, 95% CI 0.68–0.99;

Table 4. Lipid and other laboratory parameters at baseline, mean (SD)

	mmol/l	mg/dl
Total cholesterol	4.53 ± 1.09	175 ± 42
LDL-C	2.57 ± 0.89	99 ± 34
HDL-C	1.16 ± 0.40	45 ± 15
Triglycerides	1.75 ± 1.06	155 ± 93
ApoB, mg/dl	81.7 ± 24.4	
ApoA-I, mg/dl	121.7 ± 27.1	
ApoB/ApoA-I ratio	0.700 ± 0.250	
Oxidised LDL, U/l	34.2 ± 13.8	
Haemoglobin, g/dl	11.68 ± 1.60	
Haematocrit, vol%	35.0 ± 4.9	
Albumin, g/l	39.7 ± 3.5	
Calcium, mmol/l	2.343 ± 0.220	
Phosphate, mmol/l	1.793 ± 0.550	

To convert mg/dl to mmol/l, multiply by 0.02586 for cholesterol and by 0.01129 for triglycerides.

Table 5. Comparison of study design and baseline entry criteria for the 4D [29, 39] and AURORA studies

	4D	AURORA
Countries	1 (Germany)	25
Randomised patients, n	1,225	2,775
Age group	18–80 years	50–80 years
Length of dialysis treatment	≤ 2 years	≥ 3 months
LDL-C, mmol/l (mg/dl)	2.1–4.9 (80–190)	not specified
TG, mmol/l (mg/dl)	≤ 11.3 (1,000)	not specified
History of diabetes	Yes	not required
Duration of study	4 years ^a	~ 4.6 years ^b
Study drug	atorvastatin 20 mg	rosuvastatin 10 mg
Primary endpoint	composite of death from cardiac causes, fatal stroke, non-fatal MI, or non-fatal stroke	major cardiovascular event (i.e. non-fatal MI, non-fatal stroke or cardiovascular death)
Study design	national (Germany), multicentre, randomised, double-blind, placebo controlled, parallel group	international, multicentre, randomised, double-blind, placebo controlled, parallel group

^a Mean follow-up. ^b From first patient enrolled to last patient out.

To convert mg/dl to mmol/l, multiply by 0.02586 for cholesterol and by 0.01129 for TG.

$p = 0.03$). Other individual components of the primary endpoint and other secondary endpoints (e.g. death from all causes and all cerebrovascular events combined) did not differ significantly between the atorvastatin and placebo groups. The absence of a stroke benefit and the increase in fatal strokes led the investigators to speculate that the pathogenesis of vascular events in diabetes mellitus patients who are receiving dialysis may, at least in part, be different from that in patients without ESRD.

The study design and patient populations in AURORA and 4D differ in several respects (table 5). First, patients with diabetes (type 1 or 2) comprised 26% of the AURORA patient group (fig. 2), whereas all patients in the 4D study had type 2 diabetes. Second, patients were eligible for AURORA irrespective of their lipid profile and mean lipid levels were markedly lower than in the 4D population (table 5). Third, there was no upper limit on the duration of haemodialysis for inclusion in AURORA whereas patients in 4D were required to have been receiving haemodialysis for less than 2 years (mean duration approximately 8 months). Fourth, AURORA randomised 2,775 patients from 25 different countries whereas 4D was conducted in fewer patients (1,255) from a single country (Germany). Fifth, the statin treatment in both studies differed. Statin treatment in AURORA is rosuvastatin 10 mg once daily and in 4D it was atorvastatin 20 mg once daily (both studies had a placebo arm). Finally, although the lower age limit for inclusion in AURORA was 50 years, the mean age (64.2 years; SD 8.7) was similar to that in the 4D study (65.7 years; SD 8.3), which recruited patients aged ≥ 18 years.

The ALERT trial assessed the effects of fluvastatin therapy in renal transplant recipients [33], for whom cardiovascular risk is considerably decreased compared with patients with ESRD [4]. Although the 17% risk reduction (112 vs. 134 events) with fluvastatin versus placebo for the primary endpoint (occurrence of a major adverse cardiac event) was not significant, there were significantly fewer cardiac deaths or non-fatal MIs (35% risk reduction vs. placebo; 70 vs. 104 events, $p < 0.005$). In both groups (fluvastatin and placebo), 15% had experienced a cardiac, cerebrovascular or other vascular event at baseline, which was lower than the predicted rate, leading to insufficient power to detect a significant reduction in the primary endpoint. In the ALERT extension study, patients receiving fluvastatin had a significant reduction in the relative risks of a major adverse cardiac event (risk reduction, 21%; 137 vs. 174 events; $p = 0.036$) and of a cardiac death or non-fatal MI (risk reduction 29%; 95 vs. 128 events; $p = 0.014$) compared with placebo [43].

The ongoing SHARP study is investigating the effect of simvastatin and ezetimibe on the frequency of major cardiovascular events in $\sim 9,000$ patients with CKD ($\sim 3,000$ on dialysis) who do not have established coronary heart disease [42]. The study commenced in July 2003 and is expected to complete in December 2010.

The effects of rosuvastatin 10 mg and atorvastatin 20 mg on a range of lipid levels in high-risk patients with hypercholesterolaemia were assessed in the PULSAR (Prospective study to evaluate the Utility of Low doses of the Statins Atorvastatin and Rosuvastatin) trial. Rosuvastatin was significantly more effective than atorvastatin at improving LDL-C levels (-45% vs. -43% mean change from baseline; $p = 0.05$) and HDL-C levels (6.4% vs. 3.1% mean change from baseline; $p < 0.001$) in this patient group [44].

The recently reported Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study assessed the effects of atorvastatin 80 mg on patients with no known coronary heart disease who had experienced a stroke or transient ischaemic attack (TIA) within 1–6 months of study entry. The study followed 4,731 patients over 5 years and found that atorvastatin reduced the overall incidence of both stroke (absolute reduction in risk 2.2%, $p = 0.03$) and cardiovascular events (absolute reduction in risk 3.5%, $p = 0.002$) compared with placebo, despite a small increase in the number of hemorrhagic strokes. Baseline TC, LDL-C and HDL-C lipid levels were higher and TG levels were lower in SPARCL patients compared with AURORA patients [45]. The specific effects on stroke that may occur in AURORA, although the AURORA study was not designed to elicit them, could help to understand the conflicting outcomes on stroke seen in the SPARCL and 4D studies.

Rosuvastatin is the most effective statin for lowering LDL-C [46–48] and, in AURORA, it is expected that LDL-C will be reduced to levels below those previously achieved in other statin outcomes studies, due to the low baseline values in this population.

In conclusion, preliminary baseline data from the AURORA study show a representative population of patients with ESRD receiving haemodialysis. The expected results from this study have the potential to show the effect of statin therapy in improving cardiovascular outcomes in patients with ESRD and will help guide the optimal management of this patient population.

Acknowledgements

We gratefully acknowledge the invaluable contributions of the Steering Committee, the Data and Safety Monitoring Board, the Clinical Endpoint Committee and all investigators and coordinators to the implementation of this study. We would also like to thank Dr. Margaret Duggan-Keen and Shirley Smith, from Prime Medica, who provided medical writing support on behalf of AstraZeneca.

Appendix

Executive Steering Committee

Professor B. Fellström (Principal Investigator; Uppsala, Sweden), Professor F. Zannad (Toul, France), Professor R. Schmieder (Erlangen, Germany), Dr. H. Holdaas (Oslo, Norway), Professor A. Jardine (Glasgow, UK).

Steering Committee

Executive Steering Committee members plus Dr. K. Bannister (Adelaide, Australia), Dr. J. Beutler (Den Bosch, The Netherlands),

Professor D. Chae (Kyungki-Do, Seoul, South Korea), Professor S.M. Cobbe (Glasgow, UK), Professor C. Gronhagen-Riska (Helsinki, Finland), Dr. J. Lima (Sao Paulo, Brazil), Professor R. Lins (Antwerpen, Belgium), Dr. A. McMahon (Edmonton, Canada), Professor G. Mayer (Innsbruck, Austria), Professor H.-H. Parving (Gentofte, Denmark), Dr. C. Ramos (San Luis Potosí, Mexico), Professor G. Remuzzi (Bergamo, Italy), Professor O. Samuelsson (Goteborg, Sweden), Professor S. Sonkodi (Szeged, Hungary), Dr. G. Suleymanlar (Antalya, Turkey), Professor V. Tesar (Prague, Czech Republic), Dr. D. Tsakiris (Veria, Greece), Professor V. Todorov (Pleven, Bulgaria), Professor A. Wiecek (Katowice, Poland), Professor R. Wüthrich (St. Gallen, Switzerland).

Data and Safety Monitoring Board

Professor H. Dargie (Chair; Glasgow, UK), Professor E. Ritz (Heidelberg, Germany), Professor H. Wedel (Goteborg, Sweden), Professor A.H. Zwinderman (Amsterdam, The Netherlands).

Clinical Endpoint Committee

Professor S.M. Cobbe (Chair; Glasgow, UK), Dr. A. Brady (Glasgow, UK), Dr. C. Deighan (Glasgow, UK), Professor P. Macfarlane (Glasgow, UK), Professor D. Stott (Glasgow, UK).

References

- 1 Moeller S, Gioberge S, Brown G: ESRD patients in 2001: global overview of patients, treatment modalities and development trends. *Nephrol Dial Transplant* 2002;17: 2071–2076.
- 2 Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events and hospitalization. *N Engl J Med* 2004;351: 1296–1305.
- 3 US Renal Data System: Annual Data Report. Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2005.
- 4 Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. *Am J Kidney Dis* 1998; 32:S112–S119.
- 5 Parfrey PS: Cardiac disease in dialysis patients: diagnosis, burden of disease, prognosis, risk factors and management. *Nephrol Dial Transplant* 2000;15(suppl 5):58–68.
- 6 Levey AS, Beto JA, Coronado BE, Eknayan G, Foley RN, Kasiske BL, Klag MJ, Mailloux LU, Manske CL, Meyer KB, Parfrey PS, Pfeffer MA, Wenger NK, Wilson PW, Wright JT Jr: Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. *Am J Kidney Dis* 1998;32:853–906.
- 7 Mackay J, Mensah GA: The Atlas of Heart Disease and Stroke. Geneva, World Health Organization, 2004.
- 8 4S (Scandinavian Simvastatin Survival Study Group): Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet* 1994; 344:1383–1389.
- 9 Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ; West of Scotland Coronary Prevention Study Group: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. *N Engl J Med* 1995;333:1301–1307.
- 10 Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. *Cholesterol and Recurrent Events Trial Investigators. N Engl J Med* 1996;335:1001–1009.
- 11 Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Krueyer W, Gotto AM Jr: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. *Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA* 1998;279:1615–1622.
- 12 The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. *N Engl J Med* 1998; 339:1349–1357.
- 13 Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. *Lancet* 2002;360:7–22.
- 14 Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG; PROSPER study group: PROSpective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. *Lancet* 2002; 360:1623–1630.
- 15 Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Östergren J; ASCOT investigators: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. *Lancet* 2003;361:1149–1158.
- 16 Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil H, Livingstone S, Thomason MJ, Mackness MI, Charlton-Mennys V, Fuller JH; CARDS investigators: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. *Lancet* 2004;364:685–696.

- 17 Shoji T, Nishizawa Y, Kawagishi T, Tanaka M, Kawasaki K, Tabata T, Inoue T, Morii H: Atherogenic lipoprotein changes in the absence of hyperlipidemia in patients with chronic renal failure treated by hemodialysis. *Atherosclerosis* 1997;131:229–236.
- 18 Shoji T, Nishizawa Y, Kawagishi T, Kawasaki K, Taniwaki H, Tabata T, Inoue T, Morii H: Intermediate-density lipoprotein as an independent risk factor for aortic atherosclerosis in hemodialysis patients. *J Am Soc Nephrol* 1998;9:1277–1284.
- 19 Deighan CJ, Caslake MJ, McConnell M, Boulton-Jones JM, Packard CJ: Atherogenic lipoprotein phenotype in end-stage renal failure: origin and extent of small dense low-density lipoprotein formation. *Am J Kidney Dis* 2000;35:852–862.
- 20 Stenvinkel P, Heimbürger O, Paulter F, Diczfalusy U, Wang T, Berglund L, Jøgestrand T: Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. *Kidney Int* 1999;55:1899–1911.
- 21 Annuk M, Zilmer M, Lind L, Linde T, Fellström B: Oxidative stress and endothelial function in chronic renal failure. *J Am Soc Nephrol* 2001;12:2747–2752.
- 22 Annuk M, Lind L, Linde T, Fellström B: Impaired endothelium-dependent vasodilation in renal failure in humans. *Nephrol Dial Transplant* 2001;16:302–306.
- 23 Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, Wanner C, Zoccali C: Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. *Nephrol Dial Transplant* 2003;18:1272–1280.
- 24 Laufs U: Beyond lipid-lowering: effects of statins on endothelial nitric oxide. *Eur J Clin Pharmacol* 2003;58:719–731.
- 25 Rosenson RS: Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. *Atherosclerosis* 2004;173:1–12.
- 26 Field KM: Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on high-sensitivity C-reactive protein levels. *Pharmacotherapy* 2005;25:1365–1377.
- 27 Seliger SL, Weiss NS, Gillen DL, Kestenbaum B, Ball A, Sherrard DJ, Stehman-Breen CO: HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. *Kidney Int* 2002;61:297–304.
- 28 National Kidney Foundation: K/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease. *Am J Kidney Dis* 2003;41(suppl 3):S1–S92.
- 29 Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, Ritz E; for the German Diabetes and Dialysis Study Investigators: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. *N Engl J Med* 2005;353:238–242.
- 30 Blasetto JW, Stein EA, Brown WV, Chitra R, Raza A: Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups. *Am J Cardiol* 2003;91:3C–10C.
- 31 Chapman MJ, Caslake M, Packard C, McTaggart F: New dimension of statin action on ApoB atherogenicity. *Clin Cardiol* 2003;26(1 suppl 1):I7–I10.
- 32 Fellström B, Zannad F, Schmieder R, Holdaas H, Jardine A, Rose H, Wilpshaar W; AURORA Study Group: Effect of rosuvastatin on outcomes in chronic haemodialysis patients: design and rationale of the AURORA study. *Curr Control Trials Cardiovasc Med* 2005;6:9.
- 33 Holdaas H, Fellström B, Jardine AG, Holme I, Nyberg G, Fauchald P, Gronhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Ambuhl P, Olsson AG, Hartmann A, Solbu DO, Pedersen TR; Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators: Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. *Lancet* 2003;361:2024–2031.
- 34 Jindal KK, Manuel A, Goldstein MB: Percent reduction in blood urea concentration during hemodialysis (PRU): a simple and accurate method to estimate Kt/V urea. *ASAIO Trans* 1987;33:286–288.
- 35 National Kidney Foundation: K/DOQI clinical practice guidelines for anemia of chronic kidney disease, 2000. *Am J Kidney Dis* 2001;27(suppl 1):S182–S238.
- 36 Locatelli F, Aljama P, Barany P, Canaud B, Carrera F, Eckardt KU, Horl WH, Macdougall IC, Macleod A, Wiecek A, Cameron S; European Best Practice Guidelines Working Group: Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. *Nephrol Dial Transplant* 2004;19(suppl 2):iii–ii47.
- 37 Kronenberg F, König P, Neyer U, Auinger M, Pribasnig A, Lang U, Reitingner J, Pinter G, Utermann G, Dieplinger H: Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. *J Am Soc Nephrol* 1995;6:110–120.
- 38 Kushiya F, Wada H, Sakakura M, Mori Y, Gabazza EC, Nishikawa M, Nobori T, Noguchi M, Izumi K, Nakasaki T, Takagi M, Shiku H: Effects of lipid abnormalities on arteriosclerosis and hemostatic markers in patients under hemodialysis. *Clin Appl Thromb Hemost* 2003;9:203–210.
- 39 Wanner C, Krane V, März W, Olschewski M, Asmus HG, Kramer W, Kuhn KW, Kutemeyer H, Mann JF, Ruf G, Ritz E; Deutsche Diabetes-Dialyse-Studie (4D) Study Group: Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics. *Kidney Blood Press Res* 2004;27:259–266.
- 40 Meisinger C, Baumert J, Khuseynova N, Loewel H, Koenig W: Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the general population. *Circulation* 2005;112:651–657.
- 41 Diepeveen SH, Verhoeven GW, Van Der Palen J, Dikkeschei LD, Van Tits LJ, Kolsters G, Offerman JJ, Bilo HJ, Stalenhoef AF: Effects of atorvastatin and vitamin E on lipoproteins and oxidative stress in dialysis patients: a randomised-controlled trial. *J Intern Med* 2005;257:438–445.
- 42 Baigent C, Landry M: Study of Heart and Renal Protection (SHARP). *Kidney Int* 2003;63(suppl 84):207–210.
- 43 Holdaas H, Fellström B, Cole E, Nyberg G, Olsson AG, Pedersen TR, Madsen S, Gronhagen-Riska C, Neumayer HH, Maes B, Ambuhl P, Hartmann A, Staffler B, Jardine AG; Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators: Long term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. *Am J Transplant* 2005;5:2929–2936.
- 44 Clearfield MB, Amerena J, Bassand JP, Garcia HR, Miller SS, Sosef FF, Palmer MK, Bryzinski BS: Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia: Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR). *Trials* 2006;7:35.
- 45 Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, Silleisen H, Simunovic L, Szarek M, Welch KM, Zivin JA; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators: High-dose atorvastatin after stroke or transient ischemic attack. *N Engl J Med* 2006;355:549–559.
- 46 Ballantyne CM, Bertolami M, Hernandez Garcia HR, Nul D, Stein EA, Theroux P, Weiss R, Cain VA, Raichlen JS: Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY) II. *Am Heart J* 2006;151:975.e1–e9.
- 47 Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW; STELLAR Study Group: Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). *Am J Cardiol* 2003;92:152–160.
- 48 Schuster H, Barter PJ, Stender S, Cheung RC, Bonnet J, Morrell JM, Watkins C, Kallend D, Raza A; Effective Reductions in Cholesterol Using Rosuvastatin Therapy I Study Group: Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol using Rosuvastatin therapy (MERCURY I) study. *Am Heart J* 2004;147:705–712.